Headline Post

5 articles this week

Latest

Amanat (AMAN) to Combine with Corxel US in $228M Deal

Amanat (NASDAQ:AMAN) has entered into a definitive agreement to combine with biotech firm Corxel Pharmaceuticals at an enterprise value of $228 million. Corxel is developing an oral GLP-1 weight-loss drug as well as other potential treatments. More

Nicholas Alan Clayton·Oct 26

Morning SPAC News Roundup: October 26, 2026

With just one week left in October, the month has currently represented a slowdown in SPAC IPOs, with just four teams pricing their vehicles since October 1. More

Nicholas Alan Clayton·Oct 26

SPAC IPO Terms Tracker: October 23, 2026

Terms Tracker for the Week Ending October 23, 2026 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week's pricings. It was a very quiet week with zero SPAC IPOs priced and zero new SPACs filed, but there were two new deals announced to bring the year-to-date announcement count to 85. More

Kristi Marvin·Oct 24

APEX Tech (TRAD) to Combine with Korai Flix in $3.5Bn Deal

APEX Tech (NYSE:TRAD) has entered into a definitive agreement to combine with South Korean film studio Korai Flix at a $3.5 billion pre-money equity value. Korai Flix has launched an online content platform that provides AI-generated short films and allows users to produce their own interactive content with AI avatars. More

Nicholas Alan Clayton·Oct 21

Podcast: Elroy Air on Expanding the Role of Drones in Defense and Logistics

This week, we speak with Andrew Clare, CEO of Elroy Air, which announced a $961 million business combination with Inflection Point Acquisition Corp. VII (NASDAQ:IPXG) in June. Drones are suddenly everywhere, but very few can handle jobs that require heavy lift along with vertical takeoff. More

Kristi Marvin·Oct 21

TCGX (TCGX) to Combine with TriGemX Bio in $403M Deal

TCGX I (NASDAQ:TCGX) has signed a definitive agreement to combine with drug developer TriGemX Bio at a pro forma enterprise value of $402.8 million. New York-based TriGemX Bio is developing a drug candidate for the treatment of acute migraines that is currently in Phase III trials. More

Nicholas Alan Clayton·Oct 19

SPAC IPO Terms Tracker: October 16, 2026

Terms Tracker for the Week Ending October 16, 2026 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week's pricings. Two more IPOs priced this week, bringing the October count to four and the 2026 year-to-date count to 156. More

Kristi Marvin·Oct 17

New SPAC: EuroSPAC Acquisition Corp. Files for $125M IPO

EuroSPAC Acquisition Corp. has filed for a $125 million SPAC with a team made up of executives from the shipping industry. The new SPAC is offering investors 1/2 warrants in its units with no overfunding of its trust and a 24-month transaction deadline. More

Nicholas Alan Clayton·Oct 16

TCGX Acquisition Corp. II (TCXB) Prices $100M IPO

TCGX Acquisition Corp. II (NASDAQ:TCXB) announced the pricing of its $100 million IPO and its shares are expected to begin trading on the Nasdaq under the symbol "TCXB" on Friday, October 16, 2026. More

Nicholas Alan Clayton·Oct 15

Top 3 SPAC Targets – Insurance

In the last iteration of this column, SPACInsider took a look at some industries and targets that should be high on a SPAC team’s list, especially should inflation and interest rate pressures force a renewed focus on cash-generating targets. More

Nicholas Alan Clayton·Oct 15